TOP2A
Basic information
Region (hg38): 17:40388525-40417896
Previous symbols: [ "TOP2" ]
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the TOP2A gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 9 | |||||
missense | 65 | 10 | 77 | |||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 1 | 1 | ||||
non coding | 0 | |||||
Total | 0 | 0 | 65 | 14 | 7 |
Variants in TOP2A
This is a list of pathogenic ClinVar variants found in the TOP2A region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
17-40389558-T-C | not specified | Uncertain significance (Apr 06, 2024) | ||
17-40389575-G-A | not specified | Uncertain significance (Oct 10, 2023) | ||
17-40389582-T-G | not specified | Uncertain significance (Dec 27, 2022) | ||
17-40389620-G-A | not specified | Uncertain significance (Nov 11, 2024) | ||
17-40389626-C-T | not specified | Uncertain significance (Aug 04, 2024) | ||
17-40389970-T-C | not specified | Uncertain significance (Sep 15, 2021) | ||
17-40390022-A-C | TOP2A-related disorder | Benign (May 30, 2019) | ||
17-40390108-T-C | not specified | Uncertain significance (May 12, 2024) | ||
17-40390129-T-C | not specified | Uncertain significance (Feb 10, 2022) | ||
17-40390141-C-A | not specified | Uncertain significance (Apr 26, 2023) | ||
17-40390141-C-T | not specified | Uncertain significance (Dec 18, 2023) | ||
17-40391509-T-G | not specified | Uncertain significance (May 18, 2023) | ||
17-40391561-T-C | Likely benign (Sep 01, 2022) | |||
17-40391623-C-T | not specified | Uncertain significance (Oct 06, 2024) | ||
17-40392074-C-T | not specified | Likely benign (Oct 17, 2023) | ||
17-40392094-A-G | not specified | Uncertain significance (Mar 29, 2022) | ||
17-40392210-A-G | Benign (Jun 23, 2018) | |||
17-40392277-A-C | Benign (Dec 31, 2019) | |||
17-40392296-G-A | not specified | Uncertain significance (Nov 18, 2022) | ||
17-40392298-G-T | not specified | Uncertain significance (Aug 11, 2022) | ||
17-40392315-C-A | not specified | Uncertain significance (Dec 30, 2023) | ||
17-40392335-G-C | not specified | Uncertain significance (Oct 13, 2023) | ||
17-40392626-A-G | not specified | Uncertain significance (Oct 10, 2023) | ||
17-40392636-C-T | not specified | Uncertain significance (Jan 16, 2024) | ||
17-40392726-T-C | not specified | Uncertain significance (May 16, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
TOP2A | protein_coding | protein_coding | ENST00000423485 | 35 | 29435 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.991 | 0.00914 | 124609 | 0 | 45 | 124654 | 0.000181 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 4.04 | 448 | 762 | 0.588 | 0.0000378 | 10175 |
Missense in Polyphen | 84 | 275.11 | 0.30534 | 3647 | ||
Synonymous | 1.70 | 221 | 256 | 0.865 | 0.0000126 | 2692 |
Loss of Function | 6.75 | 15 | 80.2 | 0.187 | 0.00000437 | 1057 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000556 | 0.000540 |
Ashkenazi Jewish | 0.000103 | 0.0000993 |
East Asian | 0.0000618 | 0.0000556 |
Finnish | 0.0000469 | 0.0000464 |
European (Non-Finnish) | 0.000201 | 0.000195 |
Middle Eastern | 0.0000618 | 0.0000556 |
South Asian | 0.000341 | 0.000294 |
Other | 0.000165 | 0.000165 |
dbNSFP
Source:
- Function
- FUNCTION: Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segregation of daughter chromosomes. May play a role in regulating the period length of ARNTL/BMAL1 transcriptional oscillation (By similarity). {ECO:0000250|UniProtKB:Q01320, ECO:0000269|PubMed:18790802, ECO:0000269|PubMed:22013166, ECO:0000269|PubMed:22323612}.;
- Pathway
- Doxorubicin Pathway (Cancer Cell), Pharmacodynamics;Etoposide Pathway, Pharmacokinetics/Pharmacodynamics;Etoposide Action Pathway;Teniposide Action Pathway;Teniposide Metabolism Pathway;Etoposide Metabolism Pathway;Mitotic G1-G1-S phases;Gastric Cancer Network 1;Gastric Cancer Network 2;Retinoblastoma (RB) in Cancer;Post-translational protein modification;SUMOylation of DNA replication proteins;SUMO E3 ligases SUMOylate target proteins;Metabolism of proteins;Transcription of E2F targets under negative control by DREAM complex;G0 and Early G1;Mitotic G1-G1/S phases;SUMOylation;Cell Cycle;Cell Cycle, Mitotic;Validated transcriptional targets of deltaNp63 isoforms
(Consensus)
Recessive Scores
- pRec
- 0.545
Intolerance Scores
- loftool
- 0.689
- rvis_EVS
- 0.49
- rvis_percentile_EVS
- 79.61
Haploinsufficiency Scores
- pHI
- hipred
- Y
- hipred_score
- 0.756
- ghis
- 0.592
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.960
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Top2a
- Phenotype
Zebrafish Information Network
- Gene name
- top2a
- Affected structure
- neural tube
- Phenotype tag
- abnormal
- Phenotype quality
- apoptotic
Gene ontology
- Biological process
- resolution of meiotic recombination intermediates;sister chromatid segregation;hematopoietic progenitor cell differentiation;DNA topological change;DNA ligation;cellular response to DNA damage stimulus;chromosome segregation;female meiotic nuclear division;apoptotic chromosome condensation;embryonic cleavage;regulation of circadian rhythm;positive regulation of apoptotic process;mitotic DNA integrity checkpoint;positive regulation of single stranded viral RNA replication via double stranded DNA intermediate;positive regulation of transcription by RNA polymerase II;rhythmic process;negative regulation of DNA duplex unwinding
- Cellular component
- nuclear chromosome;condensed chromosome;nucleus;nucleoplasm;nucleolus;centriole;DNA topoisomerase complex (ATP-hydrolyzing);viral integration complex;protein-containing complex;ribonucleoprotein complex
- Molecular function
- magnesium ion binding;DNA binding;chromatin binding;RNA binding;DNA topoisomerase type II (ATP-hydrolyzing) activity;protein kinase C binding;protein binding;ATP binding;protein C-terminus binding;DNA-dependent ATPase activity;drug binding;DNA binding, bending;enzyme binding;protein homodimerization activity;histone deacetylase binding;ubiquitin binding;protein heterodimerization activity